Summary: Anthracycline-induced cardiotoxicity remains a significant contributor to late morbidity/mortality in children and young adults with acute myeloid leukemia (AML). The cardioprotectant dexrazoxane can be used as prophylaxis to diminish risk for cardiomyopathy but whether it affects risk of relapse in pediatric AML is unclear. Our institution adopted the use of dexrazoxane before anthracyclines administration for all oncology patients in 2011. We compared patients with AML (ages, 0 to 21 y) who received or did not receive dexrazoxane during the years 2008 to 2013. In total, 44 patients with AML (ages, 4.5 mo to 21.7 y) were included. We identified no statistical difference in 2-year event rate (62% vs. 50%, P = 0.41) or 2-year overall survival (69% vs. 69%, P = 0.53) between patients receiving (n = 28) or not receiving (n = 16) dexrazoxane. Ejection fraction (P = 0.0262) and shortening fraction (P = 0.0381) trended significantly higher in patients that received dexrazoxane compared with those that did not receive dexrazoxane. Utilization of the cardioprotectant dexrazoxane before anthracycline chemotherapy in pediatric patients with AML demonstrated no significant difference in either event rate or overall survival relative to institutional controls and seems to improve cardiac function indices. Further studies in this patient population are needed to confirm these findings.
A cute myeloid leukemia (AML) comprises 5% of pediatric cancers and reports 5-year event free survival of B50% with overall survival (OS) approaching 70% following intensive multiagent chemotherapy. [1] [2] [3] [4] Pediatric cancer survivors who received intensive treatment, such as those with AML, have a 73% incidence of developing a chronic health condition and 42% chance of having a severe, disabling, life-threatening condition, or death from a chronic condition. 5 Importantly the absence of a plateau in chronic condition incidence over 30 years of follow-up is most concerning. 5 Thus, identifying interventions to minimize the long-term morbidity and/or mortality in pediatric patients with AML remains a priority for the oncology community.
Anthracyclines have been the cornerstone to treatment in AML since the 1960s and continue to be used today for de novo AML. The specific anthracyclines used include: daunorubicin, idarubicin, and mitoxantrone. All 3 of these anthracyclines are cardiotoxic carrying the risk for both acute and late cardiac complications which can include arrhythmias, cardiomyopathy, and congestive heart failure (CHF). These risks increase as the cumulative anthracycline dose increases. 6-10 Nearly 1 in 10 pediatric patients receiving anthracyclines will develop CHF in 20 years with significantly higher incidence when the cumulative dose is >300 mg/m 2 . 11 Importantly, current treatment for children with AML includes cumulative anthracycline doses in excess of 300 mg/m 2 which places these children at greater risk for developing CHF.
The predominant mechanism for antitumor activity of anthracyclines is DNA intercalation and topoisomerase II inhibition, which interfere with chromatin and inhibit replication of the DNA. The primary cause of anthracyclineinduced cardiotoxicity is believed to be oxygen free-radical generation. 12, 13 Dexrazoxane was first developed as a topoisomerase II inhibitor chemotherapy agent but demonstrated poor antitumor effects. 14, 15 However, it also acts as an oxygen free-radical chelator, and when given before anthracycline chemotherapy, is able to bind to the free radicals and prevent long-term cardiac toxicities. [16] [17] [18] Topoisomerase II inhibitors, including dexrazoxane, have been implicated in higher rates of secondary malignant neoplasm (SMN) development but the association with dexrazoxane has been debated in multiple studies. [19] [20] [21] [22] However, due to the potential for negative antileukemic effects as well as the concern for an increased risk of secondary malignancies, dexrazoxane has been utilized in only 2% of de novo pediatric AML patients or when patients have received a cumulative anthracycline exposure >400 to 450 mg/m 2 . 23 Pediatric leukemia studies incorporating dexrazoxane have demonstrated no increase in relapse risk, 14, 21, [24] [25] [26] [27] and improvement in cardiac indices 14, [24] [25] [26] [27] [28] ; however, these data are limited to regimens using lower overall anthracycline doses and lack adequate control groups. 14, 21, [23] [24] [25] [26] [27] [28] [29] [30] Because of the known cardiac risk to pediatric patients who receive high cumulative doses of anthracyclines over their lifetime, we adopted a standardized clinical practice at the Children's Hospital of Wisconsin 
MATERIALS AND METHODS
We performed a retrospective chart review of children ages 0 to 21 years who received their therapy for AML at CHW between January 1, 2008 and December 31, 2013. In 2011, the oncology division at CHW adopted a clinical practice of administering dexrazoxane before any nonliposomal anthracycline chemotherapy unless specifically restricted by a clinical trial in which a patient was enrolled. This study was approved by the CHW institutional review board before data collection.
Data were collected from the CHW electronic medical record (Sunrise Acute Care, Eclipsys Corporation, Atlanta, GA and EPIC, EPIC Systems Corporation, Verona, WI). Data included patient demographics, date of diagnosis, French-American-British leukemia classification, cytogenetic abnormalities, bone marrow evaluation, complete blood counts, central nervous system disease status, presence of chloroma, leukemia treatment plan, anthracycline administration, hematopoietic stem cell transplantation date, echocardiogram date, structural cardiac abnormalities, echocardiogram left ventricular (LV) ejection fraction (EF) and shortening fraction (SF), LV mass (g), LV Mass index (g/ht 2.7 ), hypertension status, relapse status, treatment-related mortality, transplant-related mortality, disease-related mortality, and SMN. Echocardiograms were recorded at time of diagnosis, before each cycle of chemotherapy, at completion of therapy and an additional echocardiogram was obtained during off-therapy follow-up.
Cytogenetic risk status was determined based on prior definitions from the Children's Oncology Group. 31 Anthracycline dose was calculated in daunorubicin equivalents using the formula: daunorubicin equivalents (mg/m 
Statistical Analyses
Statistical analyses were conducted using SAS statistical software version 9.4 (SAS Institute Inc., Cary, NC) with 2-sided Pr0.05 considered statistically significant. Data were expressed as frequency count and percentage for categorical variables. As the data were not normally distributed, the median with lower and upper quartiles was computed for continuous variables. A nonparametric Mann-Whitney-Wilcoxon test was used to compare the continuous variables, whereas a w 2 test or the Fisher exact test was used to compare the categorical variables between dexrazoxane Yes and No groups. Kaplan-Meier survival analysis was performed to examine the event rate or OS. Event rate was defined as rate of relapse, treatment-related death, or relapse-related death. A 2-sided log-rank test was used to detect the difference in survival between patients with dexrazoxane and patients without dexrazoxane. A random coefficient model with unstructured covariance matrix was used to model the changes of cardiac indices over time. Covariance parameters were estimated using maximum likelihood. RFoundation for Statistical Computing, Vienna, Austria URL www.R-project.org/ was used for the graphs. On the basis of the number of patients in the 2 groups, a hazard ratio of 3 would achieve an 85% power to detect a significant difference between the 2 groups.
RESULTS

Relapse and Survival
A total of 53 patients with AML who received therapy at CHW were identified for this analysis. After exclusion of 9 patients who did not receive their entire de novo AML therapy at CHW, a total of 44 patients were included ages 4.5 months to 21.7 years. Of the 44 patients, 64% (n = 28) received dexrazoxane as part of their multiagent chemotherapy regimen and 36% (n = 16) did not. The study population demographics and clinical characteristics are summarized in Table 1 . There were no differences in rates of hematopoietic stem cell transplantation. We identified no statistical difference in 2-year event rate between patients who received dexrazoxane (62%) compared with those that did not (50%; P = 0.41) (Fig. 1 ). In addition, there was no difference in 2-year OS between groups (69% vs. 69%; P = 0.53, respectively) (Fig. 2 ). There were 15 (53.6%) relapses, 9 (32.1%) disease-related deaths, and 1 (3.6%) treatment-related death in the dexrazoxane group compared with 7 (43.8%) relapses, 5 (31.3%) disease-related deaths, and 1 (6.3%) treatment-related death in the nondexrazoxane group (P = 0.49). No SMNs were diagnosed in either cohort during the study period. The small sample size in this analysis limited further subgroup analysis.
Cardiac Outcomes
Baseline patient cardiac characteristics are summarized in Table 2 . Echocardiography data were collected at the time of therapy initiation, during treatment, and Figure 3 . There was a significant decrease in both EF and SF in the group that did not receive dexrazoxane compared with the dexrazoxane recipients (Figs. 3A, B) . One patient in the dexrazoxane group had their anthracyclines held due to a decline in cardiac function which was associated with a fatal sepsis event.
DISCUSSION
In pediatric and young adult patients with AML who received dexrazoxane as a cardioprotectant during their anthracycline therapy, we observed no increase in relapse or decline in OS. In addition, patients receiving dexrazoxane demonstrated improved cardiac indices following their anthracycline exposure. This is consistent with other pediatric studies in non-AML diseases where anthracyclines have been used albeit in lower cumulative doses. 17, 24 EF and SF were preserved during the study period for patients receiving dexrazoxane immediately before anthracycline administration. The decline in SF observed in the nondexrazoxane group is consistent with prior adult and pediatric studies of anthracyclines and dexrazoxane as an indicator of long-term pathologic LV remodeling. 34, 35 These trend differences while statistically significant fall within the normal clinical ranges and would not be expected to be clinically detectable. The presentation SF of the dexrazoxane group was significantly lower, but within clinical normal values at presentation. This may be indicative of subclinical cardiac impairment at presentation or act as a confounder of subsequent trends. As well, we observed only a single episode of heart failure in the dexrazoxane group which was temporally associated with a sepsis event. In addition, comparing the incidence of clinically significant cardiac events or heart failure secondary to anthracycline exposure would require a significantly longer follow-up and was not the primary aim of this analysis. 25, 36 We observed no episodes of secondary malignancies in either of our cohorts; however, distinguishing a treatmentrelated AML from a relapse would be challenging. This observation is not surprising given our relatively small patient numbers, relatively short follow-up, and the low overall rate of SMN reported in pediatric oncology of 1% to 2%. 17, 19, 21, 22, 28, 37 The implementation of dexrazoxane as a cardioprotectant at our institution affords a unique opportunity to study the effect of dexrazoxane on the cardiac toxicities and antileukemic effects in children and adolescents with AML. However, the single center and retrospective nature of our study remains a limitation. Despite these limitations, we identified no significant difference in OS or rate of relapse in patients receiving dexrazoxane immediately before anthracyclines and found improvements in both EF and SF compared with our control nondexrazoxane group. On the basis of these findings our center continues to utilize dexrazoxane before all nonliposomal anthracycline therapy in patients with AML. 
